| __timestamp | Alkermes plc | MorphoSys AG |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 55962693 |
| Thursday, January 1, 2015 | 4019000 | 78655788 |
| Friday, January 1, 2016 | 2301000 | 95723069 |
| Sunday, January 1, 2017 | 7232000 | 116808575 |
| Monday, January 1, 2018 | 68895000 | 106397017 |
| Tuesday, January 1, 2019 | 52816000 | 108431600 |
| Wednesday, January 1, 2020 | 1946000 | 141426832 |
| Friday, January 1, 2021 | 1020000 | 225200000 |
| Saturday, January 1, 2022 | 393842000 | 297812160 |
| Sunday, January 1, 2023 | 270806000 | 283614139 |
| Monday, January 1, 2024 | 245326000 |
Unleashing insights
In the competitive world of biopharmaceuticals, innovation is the lifeblood of success. Alkermes plc and MorphoSys AG, two industry leaders, have been vying for the top spot in research and development (R&D) investment since 2014. Over the past decade, MorphoSys AG has consistently outpaced Alkermes in R&D spending, with an average annual investment of approximately 151% more than Alkermes. Notably, in 2021, MorphoSys AG's R&D expenses surged to nearly double that of Alkermes, highlighting their commitment to pioneering new therapies.
However, 2022 marked a turning point. Alkermes made a significant leap, increasing their R&D investment by over 380% compared to the previous year, surpassing MorphoSys for the first time. This shift underscores Alkermes' strategic pivot towards innovation, setting the stage for an exciting rivalry in the years to come.
Research and Development Expenses Breakdown: Johnson & Johnson vs Alkermes plc
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and Alkermes plc
GSK plc or MorphoSys AG: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Takeda Pharmaceutical Company Limited and MorphoSys AG
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
Research and Development Investment: Neurocrine Biosciences, Inc. vs MorphoSys AG
Research and Development Investment: Exelixis, Inc. vs Alkermes plc
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and MorphoSys AG
Research and Development Investment: Pharming Group N.V. vs Alkermes plc
Research and Development Investment: Corcept Therapeutics Incorporated vs Alkermes plc
R&D Spending Showdown: Ionis Pharmaceuticals, Inc. vs MorphoSys AG
Key Insights on Gross Profit: Alkermes plc vs MorphoSys AG